These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10077011)

  • 21. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model.
    Turetschek K; Roberts TP; Floyd E; Preda A; Novikov V; Shames DM; Carter WO; Brasch RC
    J Magn Reson Imaging; 2001 Jun; 13(6):882-8. PubMed ID: 11382948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization.
    Ni Y; Marchal G; Yu J; Mühler A; Lukito G; Baert AL
    J Magn Reson Imaging; 1994; 4(3):355-63. PubMed ID: 8061434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paramagnetic perfluorocarbon-filled albumin-(Gd-DTPA) microbubbles for the induction of focused-ultrasound-induced blood-brain barrier opening and concurrent MR and ultrasound imaging.
    Liao AH; Liu HL; Su CH; Hua MY; Yang HW; Weng YT; Hsu PH; Huang SM; Wu SY; Wang HE; Yen TC; Li PC
    Phys Med Biol; 2012 May; 57(9):2787-802. PubMed ID: 22510713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
    Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R
    Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent.
    Sirlin CB; Vera DR; Corbeil JA; Caballero MB; Buxton RB; Mattrey RF
    Acad Radiol; 2004 Dec; 11(12):1361-9. PubMed ID: 15596374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of a binary chelate formulation: Could gadolinium based linear contrast agents be rescued by the addition of zinc selective chelates?
    Gibby W; Parish W; Merrill RM; Fernandez D; Anderson CR; Merchel E; Parr R
    Magn Reson Imaging; 2019 May; 58():76-81. PubMed ID: 30639754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of severity of myocardial injury on distribution of macromolecules: extravascular versus intravascular gadolinium-based magnetic resonance contrast agents.
    Schwitter J; Saeed M; Wendland MF; Derugin N; Canet E; Brasch RC; Higgins CB
    J Am Coll Cardiol; 1997 Oct; 30(4):1086-94. PubMed ID: 9316544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contrast-enhanced MRI of tumors. Comparison of Gd-DTPA and a macromolecular agent.
    Wikström MG; Moseley ME; White DL; Dupon JW; Winkelhake JL; Kopplin J; Brasch RC
    Invest Radiol; 1989 Aug; 24(8):609-15. PubMed ID: 2777530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor angiography using high-resolution, three-dimensional magnetic resonance imaging: comparison of gadopentetate dimeglumine and a macromolecular blood-pool contrast agent.
    Schwickert HC; Stiskal M; van Dijke CF; Roberts TP; Mann JS; Demsar F; Brasch RC
    Acad Radiol; 1995 Oct; 2(10):851-8. PubMed ID: 9419650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents.
    Marzola P; Ramponi S; Nicolato E; Lovati E; Sandri M; Calderan L; Crescimanno C; Merigo F; Sbarbati A; Grotti A; Vultaggio S; Cavagna F; Lorusso V; Osculati F
    Invest Radiol; 2005 Jul; 40(7):421-9. PubMed ID: 15973133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology.
    Turetschek K; Floyd E; Shames DM; Roberts TP; Preda A; Novikov V; Corot C; Carter WO; Brasch RC
    Magn Reson Med; 2001 May; 45(5):880-6. PubMed ID: 11323815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous MRI measurement of blood flow, blood volume, and capillary permeability in mammary tumors using two different contrast agents.
    Henderson E; Sykes J; Drost D; Weinmann HJ; Rutt BK; Lee TY
    J Magn Reson Imaging; 2000 Dec; 12(6):991-1003. PubMed ID: 11105041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights.
    Cheng HL; Wallis C; Shou Z; Farhat WA
    J Magn Reson Imaging; 2007 Jan; 25(1):137-45. PubMed ID: 17139634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regional comparison of tumor vascularity and permeability parameters measured by albumin-Gd-DTPA and Gd-DTPA.
    Su MY; Najafi AA; Nalcioglu O
    Magn Reson Med; 1995 Sep; 34(3):402-11. PubMed ID: 7500880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of tumor angiogenesis with a second-generation US contrast medium in a rat breast tumor model.
    Ko EY; Lee SH; Kim HH; Kim SM; Shin MJ; Kim N; Gong G
    Korean J Radiol; 2008; 9(3):243-9. PubMed ID: 18525227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gadolinium-free extracellular MR contrast agent for tumor imaging.
    Nofiele JT; Haedicke IE; Zhu Yle K; Zhang XA; Cheng HL
    J Magn Reson Imaging; 2015 Feb; 41(2):397-403. PubMed ID: 24399613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between phenotype and size of breast tumors induced by 1-methyl-1-nitrosourea (MNU) injection in rats.
    Jaafar H; Mohamad Idris F; Mohd Nafi SN
    Med Sci Monit; 2009 May; 15(5):BR129-34. PubMed ID: 19396029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation.
    Preda A; Novikov V; Möglich M; Floyd E; Turetschek K; Shames DM; Roberts TP; Corot C; Carter WO; Brasch RC
    Eur Radiol; 2005 Nov; 15(11):2268-75. PubMed ID: 16012822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of arsenazo III in the preparation and characterization of an albumin-linked, gadolinium-based macromolecular magnetic resonance contrast agent.
    Nagaraja TN; Croxen RL; Panda S; Knight RA; Keenan KA; Brown SL; Fenstermacher JD; Ewing JR
    J Neurosci Methods; 2006 Oct; 157(2):238-45. PubMed ID: 16769125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The performance of gadolinium diethylene triamine pentaacetate-pullulan hepatocyte-specific T1 contrast agent for MRI.
    Yim H; Yang SG; Jeon YS; Park IS; Kim M; Lee DH; Bae YH; Na K
    Biomaterials; 2011 Aug; 32(22):5187-94. PubMed ID: 21561660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.